The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing you cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
New prognostic model for survival in patients with R/R DLBCL
Summary of the new prognostic model for survival presented at ASH 2019 in patients with R/R DLBCL. The study aimed to evaluate clinical predictors of outcome at first relapse or progression...
Feb 18, 2020
Axi-cel for secondary CNS lymphoma
A retrospective analysis evaluating the efficacy and safety of axi-cel treatment in patients with secondary CNS lymphoma. The results were presented at the 61st American Society of Hematology (ASH) Annual Meeting &...
Feb 13, 2020
EMA extends the license indications for rituximab and venetoclax
The therapeutic potential of two lymphoma therapies has been broadened. The EMA has announced license extensions of rituximab and the combination of venetoclax with obinutuzumab.
Feb 12, 2020
Gilles Salles
"The Lymphoma Hub allows you to navigate the most relevant and up-to-date information in lymphoma and CLL. From recently published papers to on-site interviews, we aim to deliver valuable data to all physicians practicing hemato-oncology."